Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
73.00    -0.50 (-0.68%)
Bid:
72.00
Ask:
74.00
Spread: 2.00 (2.778%)
Market Cap: £342.04m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Sch 1 - Readybuy PLC

21 Jul 2006 10:15

AIM21 July 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Readybuy plc COMPANY ADDRESS:Television House, 10-12 Mount Street, Manchester COMPANY POSTCODE:M2 5NT COUNTRY OF INCORPORATION:England and Wales COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:Since the Readybuy group's trading activities were terminated in July 2005, the directors of Readybuy have beenexploring the future options available to the Company. The Company's investing strategy is to acquire a companyinvolved in developing enabling technologies, particularly in the defence and bio-chemistry sectors. The Boardbelieves that the proposed acquisition of Avacta meets this investment strategy. Avacta was spun-out from the University of Leeds in January 2004 by its current management team as a biophysicscompany, with the aim of combining the disciplines of physics and biology to develop innovative technologies toaddress needs in the homeland security, pharmaceutical and clinical diagnostic markets. Avacta has two core activities: the development of detection technology platforms designed to meet the needs ofits target markets; and the provision of analytical services relating to the chemical and physical analysis ofmaterials to a range of companies, principally in the pharmaceutical, healthcare and personal care sectors. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares):644,857,446 ordinary shares of 0.1p each on First Admission 24,469,898 ordinary shares of 0.1p each on Second AdmissionCAPITAL TO BE RAISED ON ADMISSION:£1,012,500 before expenses, by means of a placing of 45,000,000 ordinary shares of 0.1p each at 2.25p per share FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Directors: Daron Ross Lee (non-executive Chairman) Professor David Alastair Maclaughlin Smith (non-executive director and proposed Chief Executive followingAdmission) Proposed Directors: Dr. Gwynfor Owen Humphreys (proposed non-executive Chairman)Dr. Simon Webster (proposed Chief Scientific Officer)Dr. Kurt Justin Baldwin (proposed Chief Technology Officer)Timothy James Sykes (proposed Chief Financial Officer and proposed Company Secretary)Professor Anthony William Robards (proposed non-executive director)Alan John Aubrey (propose non-executive director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION:Before: Robert Quested (29.76%)Christopher Potts (16.96%)Stephen James (16.09%)Robert Quested, Christopher Potts and Stephen James are also interested in warrants to subscribe for 18,500,000;10,500,000; and 10,000,000 Ordinary Shares respectively. On Admission: Robert Quested (8.93%)Christopher Potts (3.15%)Stephen James (2.99%) The members of the Existing Concert Party, as at the date of this document, together hold 83.71% of the issuedshare capital of the Company, and will, immediately following the Placing and Admission hold 19.84 % thereof.The members of the New Concert Party (being the vendors of Avacta), as at the date of this document, togetherhold 0.96% of the issued share capital of the Company, and will, immediately following the Placing and Admissionhold 74.88% thereof. NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:None ANTICIPATED ACCOUNTING REFERENCE DATE:30 April EXPECTED ADMISSION DATE:8 August 2006 (First Admission)9 August 2006 (Second Admission) NAME AND ADDRESS OF NOMINATED ADVISER:WH Ireland Limited11 St James's SquareManchesterM2 6WH NAME AND ADDRESS OF BROKER:WH Ireland Limited11 St James's SquareManchesterM2 6WH DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:Copies of the admission document containing full details about the applicant and the admission of its securitieswill be available free of charge to the public until at least one month after admission at the offices of:- WH Ireland Limited11 St James's SquareManchesterM2 6WH DATE OF NOTIFICATION:21 July 2006 NEW/ UPDATE (see note):New This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Oct 20137:00 amRNSFirst therapeutic licensing agreement for Affimers
26th Sep 20137:00 amRNSLaunch of Sensipod - First Point of Care Test
18th Sep 20137:00 amRNSIssue of Equity and Notice of Preliminary Results
16th Sep 20137:00 amRNSNew Head of R&D Joins Avacta
2nd Sep 20135:47 pmRNSTR-1 Notification of Major Interest in Shares
29th Aug 20137:00 amRNSPre-close trading update
28th Aug 20137:00 amRNSIssue of Equity
9th Aug 20138:35 amRNSTR-1: Notification of Major Interest in Shares
7th Aug 20135:51 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:31 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:30 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:00 pmRNSTR-1: Notification of Major Interest in Shares
5th Aug 201311:00 amRNSResult of General Meeting
5th Aug 20137:00 amRNSAppointment of a Non-Executive Director
25th Jul 20137:00 amRNSExpansion of Collaboration with ForteBio
18th Jul 20137:00 amRNSConditional Placing to Raise £4.7 Million
23rd May 20138:40 amRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Results
23rd Apr 20137:01 amRNSNotice of Interim Results
23rd Apr 20137:00 amRNSAppointment of Nominated Advisor and Broker
27th Feb 20137:00 amRNSInterest in Affimer Technology
27th Feb 20137:00 amRNSBusiness Update
18th Feb 20135:08 pmRNSAdditional Listing
25th Jan 20132:34 pmRNSResult of AGM
21st Jan 20131:20 pmRNSHolding(s) in Company
7th Jan 20133:47 pmRNSHolding(s) in Company
23rd Oct 20127:00 amRNSPreliminary Results
24th Sep 20127:00 amRNSAvacta and Pall extend Optim distribution to India
13th Sep 201210:24 amRNSNotice of Preliminary Results
24th Aug 20127:00 amRNSPre-close trading update
19th Jun 20125:05 pmRNSHolding(s) in Company
25th Apr 20127:00 amRNSInterim Results
2nd Apr 20127:00 amRNSAvacta Signs Exclusive Supply Deal with IDEXX
15th Mar 20127:00 amRNSNotice of Interim Results
24th Jan 201210:39 amRNSResult of AGM
19th Jan 20126:23 pmRNSHolding(s) in Company
12th Jan 201211:12 amRNSHolding(s) in Company
10th Jan 20129:26 amRNSCompletes £5.13m placing and Aptuscan acquisition
9th Jan 20124:10 pmRNSResults of General Meeting
22nd Dec 20117:00 amRNSConditional Placing and Proposed Acquisition
8th Dec 20112:20 pmRNSNotice of AGM and Report and Accounts
25th Nov 20117:00 amRNSAdditional Listing & Total Voting Rights
25th Oct 20117:00 amRNSPreliminary Results
21st Oct 20117:00 amRNSAppointment of Nomad and Broker
5th Oct 20117:00 amRNSSouth East Asian Alliance agreed with Pall
19th Sep 20117:00 amRNSNotice of Preliminary Results
9th Aug 20117:00 amRNSPre-close Trading Update
6th Jul 20117:00 amRNSChange of Registered Office
10th Jun 201112:50 pmRNSDirector/PDMR Shareholding
31st May 20117:00 amRNSAvacta secures second Optim sale in US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.